<DOC>
	<DOCNO>NCT00516542</DOCNO>
	<brief_summary>RATIONALE : Androgens cause growth breast cancer cell . Hormone therapy use dehydroepiandrosterone ( DHEA ) may fight breast cancer block use androgen tumor cell . Letrozole may stop adrenal gland make androgen . Giving DHEA together letrozole may kill tumor cell . PURPOSE : This phase I trial study side effect best dose DHEA give together letrozole treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Dehydroepiandrosterone ( DHEA ) Letrozole Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To determine maximum tolerable dose , dose-limiting toxicity , pharmacokinetics dehydroepiandrosterone ( DHEA ) give together letrozole patient androgen receptor-positive estrogen receptor- progesterone receptor-negative metastatic breast cancer . OUTLINE : Patients receive oral dehydroepiandrosterone oral letrozole daily . Physical exam blood collection perform every two week . Tumor assessment perform every three month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer Metastatic disease Hormone receptor status Estrogen receptor progesterone receptornegative Androgen receptorpositive PATIENT CHARACTERISTICS : ECOG performance status 03 Postmenopausal ( &gt; 60 year age ) Leukocyte count &gt; 3,000/uL Absolute neutrophil count &gt; 1,500/uL Platelet count &gt; 100,000/uL Total bilirubin normal AST ALT &lt; 2.5 time upper limit normal Creatinine normal OR creatinine clearance &gt; 60 mL/min PRIOR CONCURRENT THERAPY : At least 4 week since prior chemotherapy At least 4 week since prior biologic therapy At least 4 week since prior radiotherapy At least 30 day since prior investigational agent No concurrent dehydroepiandrosterone androstenedione supplement No concurrent chemotherapy radiotherapy No concurrent hormone therapy immunotherapy ( include trastuzumab [ HerceptinÂ® ] )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>